Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab.
Davide AllegriniRaffaele RaimondiGiovanni MontesanoAlfredo BorgiaTania SorrentinoPanagiotis TsoutsanisMario R RomanoPublished in: Clinical ophthalmology (Auckland, N.Z.) (2021)
We detected a significant loss in visual function. The magnitude of the average loss was, however, limited suggesting good efficacy of the recovery strategy.